Zomedica Pharmaceuticals Corp. (AMEX:ZOM) does about 55.93M shares in volume on a normal day but saw 32857786 shares change hands in Friday trading. The company now has a market cap of 69.73M USD and an enterprise value of about $52.90M. Its current market price is $0.12, marking a decrease of -3.39% compared to the previous close of $0.12. The 52 week high reached by this stock is $0.50 whilst the lowest price level in 52 weeks is $0.11. The script in recent trading has seen the stock touch a high of $0.12 and a low of $0.12.
Zomedica Pharmaceuticals Corp. (ZOM) has a 20-day trading average at $0.1409 and the current price is -76.01% off the 52-week high compared with 8.82% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.1661 and its 200-day simple moving average is $0.2210. If we look at the stock’s price movements over the week, volatility stands at 7.02%, which decreases to 5.54% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 23.87 to suggest the stock is oversold.
1 analysts observing the Zomedica Pharmaceuticals Corp. (ZOM) stock have set the 12-month price targets for the company’s shares at between $0.50 and $0.50. The median price target is 76.0% away from the current levels at $0.50.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is -16.20%, -28.79%, and -46.13% away from its SMA20, SMA50, and SMA200 respectively, with the ZOM price moving above the 50-day SMA on August 28. Zomedica Pharmaceuticals Corp. (ZOM) stock is down -8.06% over the week and -25.37% over the past month. Its price is -63.84% year-to-date and -65.83% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.02 below consensus estimates by -$0.01. The company’s next earnings report is expected on 11/17/2020, with forecasts estimating quarterly EPS at $0 and -$0.03 for whole year. ZOM’s earnings per share are forecast to grow by 84.20% this year and 33.30% over next year.
Its 12-month price target is $0.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $0.50, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $0.50.
Outstanding shares total 564.05M with insiders holding 38.45% of the shares and institutional holders owning 9.67% of the company’s common stock. The company has a return on equity of 586.20%. The beta has a value of -0.20. Price to book ratio is 1.50.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Zomedica Pharmaceuticals Corp. (ZOM) to 7,964,345 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of Zomedica Pharmaceuticals Corp. common stock bringing its total worth to about $1.26 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by USAA Extended Market Index Fund, which added 19861.0 shares to end up with 31,916 shares worth $5043.0. Gabelli Equity Trust cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.00% position in Zomedica Pharmaceuticals Corp. thanks to 8688.0 shares amounting to $1373.0.